Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Crook, Derrick W., Walker, A. Sarah, Kean, Yin, Weiss, Karl, Cornely, Oliver A., Miller, Mark A., Esposito, Roberto, Louie, Thomas J., Stoesser, Nicole E., Young, Bernadette C., Angus, Brian J., Gorbach, Sherwood L., Peto, Timothy E. A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2012
Témata:
Supplement Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388031/
https://ncbi.nlm.nih.gov/pubmed/22752871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis499
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky